Socialization of Adult Men With Congenital Hemophilia A or B
NCT ID: NCT01510418
Last Updated: 2016-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
27 participants
OBSERVATIONAL
2011-05-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
NCT01217255
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
NCT02866526
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
NCT01988532
Survey Evaluating the Psychosocial Effects of Living With Haemophilia
NCT01322620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For the adult men with congenital hemophilia A or B, the study involves a minimum of 2 visits and includes screening, medical history and physical exam review, completing confidential questionnaires and interview.
Eligible men with congenital hemophilia A or B (person with congenital bleeding disorder, PWCBD) are given the option to permit the investigator to contact their spouse or significant other (SSO) for participation in the study. If PWCBD has an SSO, the SSO is not required to participate in the study.
Spouse/significant other(SSO)of men with congenital hemophilia A or B may enter the study only if they have been voluntarily identified by their partner (PWCBD) and their partner has opted to allow investigator to contact them. For the SSO who chooses to participate in the study, the study will involve a minimum of one visit and includes completing confidential questionnaires and interview.
All participation including questionnaires and interview information collected is confidential and protected by health privacy information laws and records are de-identified.
The study is sponsored by a grant from The National Hemophilia Foundation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Person with congenital bleeding disorder
Adult men with congenital hemophilia A or B
No interventions assigned to this group
Spouse/Significant Other
Spouse/significant other of person with congenital bleeding disorder participating in this study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
Eligibility criteria for spouses/significant other (SSO) participants in the study:
* A person in a relationship for a minimum of 9 months with the PWCBD participating in the study.
* PWCBD partner must be participating in the study.
* Willing to participate in questionnaire and interview on site.
\- Biologically related to PWCBD participant (that is, not a parent, sibling, child or other biologically-related caregiver).
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aric Parnes
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aric Parnes, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-343
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.